ClinicalTrials.gg
CompletedNCT01638910Updated Dec 17, 2014

Efficacy and Safety of a Combined Oral Contraceptive of Estradiol Valerate and Dienogest in Healthy Female Subjects

A Phase 3 interventional study of EV/DNG (Qlaira, BAY86-5027) in Contraception, sponsored by Bayer. Completed at 39 sites in 5 countries. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-12-17.

Sponsored by Bayer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
955
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

To evaluate the efficacy and safety of a combined oral contraceptive of estradiol valerate and dienogest in healthy female subjects.

02

Conditions studied

  • Contraception

Keywords

  • Efficacy
  • Safety
  • oral contraception
  • estradiol valerate
  • dienogest
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy women between 18 and 50 for the entire study, except women enrolled from India should be aged between 18 and 40 years, requesting
  • Smokers may not exceed 35 years of age

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation (delivery, abortion, or lactation within less than three cycles before the start of treatment)
  • (BMI) > 32 kg/m2
  • Any disease or condition that may worsen under hormonal treatment
  • Undiagnosed abnormal genital bleeding
  • Other methods such as sterilization, hormonal contraception, IUD within 30 days of Visit 1, monthly contraceptive injection within a period of three times of the injection interval before start of treatment
  • Any medication that could result in excessive accumulation, impaired metabolism, or altered excretion of the study drug or interfere with the conduct of the study or the interpretation of the results
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
955 participants (actual)

Study arms

  • Experimental
    EV/DNG (Qlaira, BAY86-5027)

    Drug: EV/DNG (Qlaira, BAY86-5027)

Interventions

  • DrugEV/DNG (Qlaira, BAY86-5027)

    Drug pages: Estradiol · Dienogest

    Oral estradiol valerate and dienogest (2 days 3.0 mg estradiol valerate (EV), 5 days 2.0 mg EV + 2.0 mg dienogest (DNG), 17 days 2.0 mg EV + 3.0 mg DNG, 2 days 1.0 mg EV, 2 days placebo), one table oral daily for 13 treatment cycles (1 cycle = 28days)

06

What researchers measure

Primary outcomes

  1. Number of unintended pregnancies

    Time frame: Up to Cycle 13 (1 Cycle = 28 days)

Secondary outcomes

  1. Number of expected bleeding days

    Time frame: Up to Cycle 13 (1 Cycle = 28 days)

  2. Number of unexpected bleeding days

    Time frame: Up to Cycle 13 (1 Cycle = 28 days)

  3. Number of expected bleeding episodes

    Time frame: Up to Cycle 13 (1 Cycle = 28 days)

  4. Number of unexpected bleeding episodes

    Time frame: Up to Cycle 13 (1 Cycle = 28 days)

  5. Number of participants with Adverse Events as a Measure of Safety and Tolerability

    Time frame: Up to Cycle 13 (1 Cycle = 28 days)

07

Study locations

39 sites
  • Guangzhou,, Guangdong 510405, China
  • Guangzhou, Guangdong 510120, China
  • Shijiazhuang, Hebei 050051, China
  • Wuhan, Hubei 430030, China
  • Wuhan, Hubei 430032, China
  • Changsha, Hunan 410013, China
  • Hengyang, Hunan 421001, China
  • Nanjing, Jiangsu 210009, China
  • Dalian, Liaoning 116011, China
  • Shenyang, Liaoning 110004, China
  • Jinan, Shandong 250012, China
  • Chengdu, Sichuan 610041, China
  • Wenzhou, Zhejiang 325027, China
  • Beijing, 100044, China
  • Beijing, 100730, China
  • Chongqing, 400016, China
  • Chongqing, 400038, China
  • Chongqing, 400042, China
  • Shanghai, 200025, China
  • Shanghai, 200030, China
  • Shanghai, 200127, China
  • Shanghai, 2100129, China
  • Tianjin, 300211, China
  • Hongkong, Hong Kong
  • Pune, Maharashtra 411001, India
  • Chandigarh, India
  • Karnal, 132001, India
  • New Delhi, 110 029, India
  • Pune, 411004, India
  • Secunderabad, 500003, India
  • Kaohsiung, 80756, Taiwan
  • Taichung, 40705, Taiwan
  • Taipei, 100, Taiwan
  • Taipei, 11217, Taiwan
  • Taipei, 116, Taiwan
  • Taoyuan, 333, Taiwan
  • Bangkok, 10330, Thailand
  • Bangkok, 10700, Thailand
  • Chiangmai, 50200, Thailand
08

References and documents

Publications

  • Yu Q, Huang Z, Ren M, Chang Q, Zhang Z, Parke S. Contraceptive efficacy and safety of estradiol valerate/dienogest in a healthy female population: a multicenter, open-label, uncontrolled Phase III study. Int J Womens Health. 2018 Jun 7;10:257-266. doi: 10.2147/IJWH.S157056. eCollection 2018. PubMed 29922096 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2012, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2012
First posted
Jul 12, 2012
Start
Jun 2012
Primary completionActual
Nov 2014
CompletionActual
Nov 2014
Last update
Dec 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01638910
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jul 12, 2012
Start date
Jun 2012
Primary completion
Nov 2014
Completion
Nov 2014
Last update
Dec 17, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Estradiol · Dienogest

Start the discussion